中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
17期
2616-2618
,共3页
恩替卡韦%干扰素%药物疗法,联合%肝炎,乙型,慢性
恩替卡韋%榦擾素%藥物療法,聯閤%肝炎,乙型,慢性
은체잡위%간우소%약물요법,연합%간염,을형,만성
Entecavir%Interferon%Drug therapy,combination%Hepatitis B,chronic
目的 探讨恩替卡韦和干扰素序贯联合治疗慢性乙型肝炎的疗效及安全性.方法 选取慢性乙型肝炎患者108例,按数字表法随机分为序贯联合组、恩替卡韦组和干扰素组三组,每组36例.观察不同治疗方法的疗效及安全性.结果 序贯联合组HBV DNA阴转率和丙氨酸氨基转移酶复常率分别为77.78％、91.67％,均明显高于恩替卡韦组和干扰素组(x2=14.40、22.12、20.07、18.47,均P＜0.05).序贯联合组总有效率为91.67％,明显高于恩替卡韦组的55.55％和干扰素组的66.67％(x2=12.09、6.82,均P＜0.05).恩替卡韦和干扰素序贯联合治疗安全性良好.结论 恩替卡韦和干扰素序贯联合治疗慢性乙型肝炎的临床疗效显著,值得在临床中推广应用.
目的 探討恩替卡韋和榦擾素序貫聯閤治療慢性乙型肝炎的療效及安全性.方法 選取慢性乙型肝炎患者108例,按數字錶法隨機分為序貫聯閤組、恩替卡韋組和榦擾素組三組,每組36例.觀察不同治療方法的療效及安全性.結果 序貫聯閤組HBV DNA陰轉率和丙氨痠氨基轉移酶複常率分彆為77.78％、91.67％,均明顯高于恩替卡韋組和榦擾素組(x2=14.40、22.12、20.07、18.47,均P＜0.05).序貫聯閤組總有效率為91.67％,明顯高于恩替卡韋組的55.55％和榦擾素組的66.67％(x2=12.09、6.82,均P＜0.05).恩替卡韋和榦擾素序貫聯閤治療安全性良好.結論 恩替卡韋和榦擾素序貫聯閤治療慢性乙型肝炎的臨床療效顯著,值得在臨床中推廣應用.
목적 탐토은체잡위화간우소서관연합치료만성을형간염적료효급안전성.방법 선취만성을형간염환자108례,안수자표법수궤분위서관연합조、은체잡위조화간우소조삼조,매조36례.관찰불동치료방법적료효급안전성.결과 서관연합조HBV DNA음전솔화병안산안기전이매복상솔분별위77.78％、91.67％,균명현고우은체잡위조화간우소조(x2=14.40、22.12、20.07、18.47,균P＜0.05).서관연합조총유효솔위91.67％,명현고우은체잡위조적55.55％화간우소조적66.67％(x2=12.09、6.82,균P＜0.05).은체잡위화간우소서관연합치료안전성량호.결론 은체잡위화간우소서관연합치료만성을형간염적림상료효현저,치득재림상중추엄응용.
Objective To discuss the efficacy and security of entecavir and interferon sequential combination therapy on chronic hepatitis B.Methods 108 patients with chronic hepatitis B were randomly divided into the sequential combination therapy group,the entecavir group and the interferon group.Each group had 36 cases.The efficacy and security of different therapy were observed.Results The HBV DNA negative rate of the sequential combination therapy group was 77.78％,and the ALT normalization rate was 91.67％,which were both higher than those of the entecavir group and the interferon group(x2 =14.40,22.12,20.07,18.47,all P ＜ 0.05).The total effective rate of the sequential combination therapy group was 91.67％,which was obviously higher than that of entecavir group and the interferon group(x2 =12.09,6.82,all P ＜ 0.05).The entecavir and interferon sequential combination therapy had a good security.Conclusion Entecavir combined with interferon sequential therapy in the treatment of chronic hepatitis B had a significant clinical efficacy and deserved promotion.
